• Product NameEndoxifen
• Brief DescriptionInhibitors
• Purification98.00%
• Biological ActivityEndoxifen is the most important Tamoxifen metabolite responsible for eliciting the anti-estrogenic effects of this drug in breast Y cells expressing estrogen receptor-alpha (ER_alpha_). Endoxifen inhibits hERG tail currents at 50 mV in a concentration-dependent manner with IC50 values of 1.6 uM.
• Target NameEGFR inhibitor; Estrogen/progestogen Receptor agonist
• CAS No. 112093-28-4
• Calculated MW 373.49
• Formulation C25H27NO2
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Endocrine system
  SMILES:CC/C(=C(\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)OCCNC)/C3=CC=CC=C3
  Pathways:Angiogenesis; Endocrinology/Hormones; JAK/STAT signaling; Tyrosine Kinase/Adaptors
  Receptor:hERG Potassium Channel; ER; ERR
  Boling pt:
  Melting pt:519.3C
  Solubility:DMSO: 10 mM
  Appearance:Purple Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Chae YJ, et al. Eur J Pharmacol. 2015 Apr 5;752:1-7.2. Wu X, et al. Breast Y Res. 2011 Mar 10;13(2):R27.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting